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Hypertension (HT) and dementia are common disorders in the elderly. HT in the elderly is associated with increased occurrence
rates of dementia including Alzheimer’s disease (AD) and vascular dementia (VaD). In connection to this, some studies have
suggested that HT in old age correlates with the pathogenesis of dementia. Since HT is potentially reversible, a number of
randomized trials have examined whether antihypertensive treatment may help in preventing dementia occurrence. We review ﬁve
studies, all using subjects 60 years or older, which investigated diﬀerent antihypertensive pharmacological treatments. Data from
two trials (Syst-Eur, PROGRESS) open the way toward the prevention of dementia (AD or VaD) by antihypertensive treatments.
In the Syst-Eur study, with the dihydropyridine calcium antagonists, a reduction in both types of dementia was demonstrated
(risk reduction 55%). The PROGRESS study showed that the use of angiotensin-converting enzyme inhibitors (ACEIs), with
or without diuretics, resulted in decrease incidence of stroke-related dementia (risk reduction 19%), but dementia without stroke
wasnotreduced.Incontrast,theSHEPtrial,treatmentwithachlorthalidone-basedantihypertensiveregimen,didnotsigniﬁcantly
reduced the incidence of dementia. The SCOPE study (candesartan or hydrochlorothiazide versus placebo) and the HYVET-COG
study (indapamide or perindopril versus placebo) found no signiﬁcant diﬀerence between the active treatment and placebo group
on the incidence of dementia. We found conﬂicting results regarding treatment beneﬁts in dementia prevention. Recent clinical
trials and studies on animal models suggest that blockades of RAS system could have reduced cognitive decline seen in Alzheimer’s
disease and vascular dementia. Future trials primarily designed to investigate the eﬀects of antihypertensive agents on impaired
cognition are needed.
1.Introduction
In general, the risk of HT, which is deﬁned as a systolic
blood pressure (SBP) ≥140mmHg and/or a diastolic blood
pressure (DBP) ≥90mmHg [1], increases with advancing
age. In fact, the prevalence of HT in individuals 60 years
and older is double that of those aged 49–59 years. In
Framingham study, 90% of all 65-year-old men and women
with normal BP later developed HT [2]. This condition
carries a very high risk for cerebrovascular disease (CVD)
as well as coronary heart disease (CHD) [3]. Dementia is
one of the most important neurological disorders in the
elderly. Many studies have identiﬁed HT as marker for the
pathogenesis of dementia AD and VaD, while longitudinal
studies have suggested that HT is associated with a higher
incidence of dementia in old age. It has been observed that
long-standing HT may lead to severe atherosclerosis and
impaired cerebrovascular autoregulation, which in turn is
thought to correlate with dementia [4]. For these reasons,
several studies have investigated whether antihypertensive
treatment may retard cognitive decline or dementia [5–9].
Although the importance of lowering BP in HT subjects
is well known, the relationship between HT and cognitive
function is controversial.
2. HT in the Elderly andthe Risk of Dementia
To this date, the associations between BP and dementia
have been inconclusive. Considering that the incidence of
dementia among the elderly population is rising rapidly
worldwide [10] and accumulating evidence that HT may
contribute to the development of both AD and VaD [11],
there is a reason to believe eﬀective management of HT may2 International Journal of Hypertension
translate into major health beneﬁts through the protection
of dementia. HT has long been known to cause CV [12].
Midlife HT ranks as an important modiﬁable risk factor
for late-life cognitive decline [13], mild cognitive impair-
ment (MCI) [14, 15], and VaD [16, 17]. In longitudinal
cohort studies, elevated BP is associated with cognitive
decline although some cross-sectional studies showed mixed
relationships between higher BP and cognition, with many
studies showing no correlation or even J- or U-shaped
associations [18]. Findings from these prospective cohort
studies for DBP and cognitive decline are less consistent;
however, many have reported a similar inverse relation. The
data on the role of BP and HT in later life are not consistent,
leaving open the issue of BP treatment in elderly people. The
controversy about the association between HT in the elderly
and dementia arises because the longitudinal relationship
between BP and cognitive change is sensitive to the eﬀects of
age, duration of followup and hypertensive treatment status,
comorbidity with CVD and CHD, and possibly subclinical
dementia [19]. More recently, a total of 668 community-
dwelling Japanese individuals without dementia, aged 65 to
79 years, were followed up for 17 years, and examined the
associations of late-life and midlife HT with the risk of AD
and VaD [20]. During the followup, 123 developed AD, and
76 subjects experienced VaD, and the age- and sex-adjusted
incidenceofVaDsigniﬁcantlyincreasedwithelevatedmidlife
BP levels regardless of late-life BP levels. There were not a
signiﬁcant association between BP levels and AD. Li et al.
[21] followed a total of 837 subjects with MCI for 5 years,
298 subjects converted to AD, while 352 remained MCI at
the end of the followup. Subjects with HT increased the risk
of dementia conversion. Given their results, treatment of HT
was associated with a reduced progression in MCI to AD
dementia.
3. CanControl of HTProtectagainstDementia?
Despite the speculated relationship between HT and demen-
tia, clinical trials examining the preventive eﬀects of anti-
hypertensive therapy on dementia have been inconclusive
(Table 1). Among ﬁve randomized double-blind placebo-
controlled trials surveying antihypertensive treatments and
dementia, four (Syst-Eur, PROGRESS, SCOPE, and HYVET-
COG) used the Mini-Mental State Examination (MMSE), a
widely used screening instrument for cognitive impairment,
to assess cognitive function. In the SHEP, cognitive screening
was performed by a short-comprehensive assessment and
referral evaluation (short CARE) questionnaire. These ﬁve
studies are described below.
3.1. Syst-Eur. The systolic hypertension in Europe study
(Syst-Eur) investigated whether antihypertensive treatment
in elderly patients with isolated systolic hypertension (ISH)
led to a signiﬁcant change in stroke morbidity and mortality.
Syst-Eur investigated the eﬀects of a calcium channel blocker
(CCB; 10–40mg/day nitrendipine). If necessary, nitrendip-
ine was combined with an ACEI (5–20 mg/d enalapril
maleate) and/or a diuretic (12.5–25mg/day hydrochloroth-
iazide). Participants had no dementia and were at least
60 years old. Their SBP at the beginning of the trial was
between 160 and 219mmHg, and their DBP was below
95mmHg. Antihypertensive therapy began immediately
after randomization in the active treatment group, but only
after termination of the double-blind trial in the control
patients. The mean diﬀerence in BP between treatment
groups and the control was 7.0mmHg SBP and 3.2mmHg
DBP; the rates of dementia for patients in the active
treatment groups and the control groups were 3.3 and 7.4
cases per 1.000 patient-years (relative risk reduction: 55%;
95% CI: 24–73%), respectively, which is signiﬁcant.
In Syst-Eur, because active treatment using a CCB
resulted in a 42% decrease in the primary end point of fatal
andnonfatalstroke,only2418ofthe4695randomlyassigned
patients participated in a substudy on dementia. Compared
with the control group, the portion of the treatment group
thatreceivedonlyCCB(60%)hadasigniﬁcantlyreducedrisk
of dementia (55%). Interestingly, while the total incidence of
dementia was 64 cases, 41 of these showed AD. Therefore,
Syst-Eur suggests using a CCB to lower BP may protect
against dementia, particularly AD, in elderlywith ISH.
3.2. PROGRESS. The perindopril protection against recur-
rent stroke study (PROGRESS) was a trial involving
6105 patients, all with prior stroke or transient ischemic
attack. Participants were assigned to either active treatment
(perindopril for all participants plus indapamide for those
with neither an indication nor a contraindication to a
diuretic) or a matching placebo. The mean diﬀerence in BP
between the two groups was 9.0mmHg SBP and 4.0 mm Hg
DBP; the rates of dementia patients in the active treatment
groups and the control groups were 6.3% and 7.1% (relative
risk reduction: 12%; 95% CI: −8 to 28%), respectively,
which is insigniﬁcant. However, the rates of cognitive decline
were 9.1 and 11.0% (risk reduction: 19%; 95% CI: 4–32%),
respectively, which is signiﬁcant.
3.3. SHEP. The systolic hypertension in the elderly program
(SHEP) study was a trial conducted over an average 5-
year follow-up and involved 16 academic clinics. Among the
447.921 candidates aged 60 years and older screened, 4736
(1.06%) were chosen for the study. SBP at baseline ranged
from 160 to 219mmHg, while DBP was less than 90mmHg.
Participants were randomized into either an active anti-
hypertensive drug therapy or a matching placebo group.
Active treatment consisted of a diuretic (12.5–25mg/day
chlorthalidone)forstep1andabetablockade(25–50mg/day
atenolol) for step 2. If atenolol was contraindicated, 0.05
to 0.10mg reserpine was used instead. The cohort mean
diﬀerence in BP between the treatment groups and placebo
was 12.0mmHg SBP and 4.0mmHg DBP; the rates of
dementia for the active treatment group and the control
group were 3.6 and 4.2 cases per 1.000 patient-years (relative
risk reduction: 14%; 95% CI: −26 to 54%), respectively,
which is insigniﬁcant.
3.4. SCOPE. The study on cognition and prognosis in the
elderly (SCOPE) was a prospective study conducted fromInternational Journal of Hypertension 3
Table 1: Randomized controlled trials about antihypertensive treatments and dementia/cognitive decline.
Study setting Participants and follow up Treatment Test Main results
Systolic hypertension in Europe
study (Syst- Eur) [5]
2.418 systolic hypertensives;
mean age 70 years, followup
3.9 years
CCB (nitrendipine) with
possible addition of ACE-I
(enalapril), diuretic
(hydrochlorothiazide), or
both versus placebo
MMSE
Mean diﬀerence in BP between
treatment groups and the control
was 7.0mm Hg SBP and
3.2mmHg DBP. Rates of
dementia for patients in the
active treatment groups and the
control groups were 3.3 and 7.4
cases per 1.000 patient-years
(relative risk reduction: 55%),
respectively. Signiﬁcant.
The perindopril protection
against recurrent stroke study
(PROGRESS) [6]
6.105 subjects with prior
stroke or transient ischemic
attack; mean age 64 years,
followup 3.9 years
ACE-I (perindopril) with
possible addition of
diuretic (indapamide)
versus placebo
MMSE
Mean diﬀerence in BP between
treatment groups and the control
was 9.0mmHg SBP and
4.0mmHg DBP. Rates of
cognitive decline for patients in
the active treatment groups and
the control groups were 11.0 and
9.1% (relative risk reduction:
19%), respectively. Signiﬁcant.
Systolic hypertension in the
elderly program (SHEP) [7]
4.736 systolic hypertensives;
mean age 72 years, followup
4.5 years
Diuretic (chlorthalidone)
with possible addition of β
blocker (atenolol) or
sympathetic nervous
blocker (reserpine) versus
placebo
Short
CARE
Mean diﬀerence in BP between
treatment groups and the control
was 12.0mmHg SBP and
4.0mmHg DBP. Rates of
dementia incidence for patients
in the active treatment groups
and the control groups were 3.6
and 4.2 cases per 1.000
patient-years (relative risk
reduction: 14%), respectively.
Not signiﬁcant.
Study on cognition and prognosis
in the elderly (SCOPE) [8]
4.964 hypertensives;
SBP160-170/DBP
90–99mmHg; aged 70– 89,
followup 3.97 years
ARB (candesartan) versus
placebo; open-label
antihypertensive drugs
w e r ea d d e dt ob o t hg r o u p s
MMSE
Mean diﬀerence in BP between
treatment groups and the control
was 3.2mmHg SBP and
1.6mmHg DBP. Rates of
dementia incidence for patients
in the active treatment groups
and the control groups were 6.3
and 6.8 cases per 1.000
patient-years, respectively. Not
Signiﬁcant.
Hypertension in the very elderly
trial cognitive function assessment
( H Y V E T -C O G )[ 9]
3.336 hypertensives; SBP
160–200 and DBP < 110 mm
Hg; age ≤80, followup 2.2
years
Diuretic (indapamide)
with possible addition of
ACE-I (perindopril) versus
placebo
MMSE
Mean diﬀerence in BP between
treatment groups and the control
was 15mmHg SBP and
5.9mmHgDBP. Rates of
dementia incidence for patients
in the active treatment groups
and the control groups were 33
and 38 cases per 1.000
patient-years (hazard ratio 0.86).
respectively. Not signiﬁcant.
BP: blood pressure, SBP: systolic blood pressure, DBP: diastolic blood pressure.
1997 to 2002. The study involved 4964 patients aged 70–
89 years with SBP ranging from 160 to 179mmHg and/or
DBP ranging from 90 to 99mmHg. Patients were assigned
randomly to receive the angiotensin II receptor blocker
(ARB) candesartan or a placebo, with open-label active anti-
hypertensivetherapyaddedas(84%ofpatientsinthecontrol
group). The mean diﬀerence in blood pressure between the
treatment group and control group was 3.2mmHg SBP
and 1.6mmHg DBP; the rates of dementia for the active
treatment group and the control group were 6.3 and 6.8 cases
per1.000patient-years,respectively,whichisinsigniﬁcant.In
a subgroup analysis of SCOPE performed later, a signiﬁcant4 International Journal of Hypertension
positive eﬀect on some cognitive domains (attention and
episodic memory) was reported when using testing methods
more sensitive than the MMSE.
3.5. HYVET-COG. The Hypertension in the very elderly
trial—cognitive function assessment (HYVET-COG) exam-
ined antihypertensive medication for patients ≥80 years of
age. Eligible patients had no dementia, their SBP at entry was
160 to 200mmHg, and their DBP was below 110mmHg.
Participants were randomly assigned to receive 1.5mg slow
release diuretic (indapamide) with the option of ACEI (2–
4mg/day, perindopril), or a placebo. The target SBP was
150/80mmHg. Possible cases of dementia (a fall in the
MMSE score to <24 or a drop of three points in one year)
were assessed by standard diagnostic criteria and expert
review. HYVET-COG was the ﬁrst randomized control
study to report the eﬀects of antihypertensive treatment in
participantsaged80yearsofageorolder,ﬁndingasigniﬁcant
decrease in stroke after an average followup of 2.2 years,
which led to its early termination. This followup period may
be too short to detect any beneﬁt preventing dementia. The
mean diﬀerence in BP between the treatment and control
groups was 15mmHg SBP and 5.9mmHg DBP; the rates of
dementia for active treatment group and the control group
were 33 and 38 cases per 1.000 patient-years (hazard ratio
0.86; 95% CI: 0.67–1.09), respectively, which is insigniﬁcant.
Of these ﬁve studies, only Syst-Eur and PROGRESS
showed signiﬁcant diﬀerences in the rate of dementia
between the treatment and control groups.
However, when four of these data (Syst-Eur, PROGRESS,
SHEP, and HYVET-COG) were combined in a meta-analysis
[22], antihypertensive therapy was found to signiﬁcantly
reduce the risk of dementia (HR 0.87, 95% CI: 0.76–1.00,
P = 0.045). Another study, however, found that combining
the antihypertensive therapy results from Syst-Eur, SHEP,
and SCOPE reduced the risk of dementia by 11% (odds
ratio 0.89; 95% CI: 0.69–1.16), an insigniﬁcant eﬀect [23].
Therefore, further long-term randomized trials, designed
especially to assess a link between antihypertensive therapy
and cognition as the primary outcome, are needed.
4. Renin-Angiotensin-AldosteroneSystem and
CognitiveFunction
Blocking the renin-angiotensin-aldosterone system (RAS) is
another means that could have beneﬁts on the prevention
of dementia [24], but in a manner independent of BP
lowering eﬀect [25]. A potential neuroprotective eﬀect on
focal cerebral ischemia has been reported by blocking the
RAS with an ARB that speciﬁcally targets the angiotensin II
receptor [26]. Moreover, the Fournier hypothesis proposes
that ARB treatment has potential advantages over ACEI
treatment in the prevention of stroke and cognitive impair-
ment because of the lower likelihood of harmful eﬀects like
vasoconstriction and proatherothrombogenesis while at the
same time promoting neutral or even potentially beneﬁcial
eﬀects like vasodilatation and endothelial modulation [27,
28].
Consistent with this theory, the ongoing telmisartan
alone and in combination with ramipril global endpoint
trial (ONTARGET) [29] and the parallel telmisartan ran-
domized assessment study in ACEI intolerant subjects
with cardiovascular disease (TRANSCEND) trial [30]h a v e
reported the eﬀects of telmisartan, a unique ARB with
peroxisome proliferator-activated receptor-gamma (PPAR-
gamma-) stimulating activity, and the ACEI ramipril on
cognitive function in patients aged 55 years and older
with established atherosclerotic cardiovascular disease or
diabetes with end-organ damage. In ONTARGET, a 56
month median duration month followup found cognitive
impairment occurred in 652 (8%) of the 7865 patients allo-
cated ramipril, 584 (7%) of the 7797 allocated telmisartan,
and 618 (8%) of the 7807 allocated a combination of the two
(combination versus ramipril, odds ratio [OR] 0.95, 95% CI
0.85–1.07, P = 0.39; telmisartan versus ramipril, OR 0.90,
0.80–1.01, P = 0.06). Corresponding ﬁgures for cognitive
decline were 1314 (17%), 1279 (17%), and 1240 (17%),
respectively(telmisartanversusramipril,OR0.97,0.89–1.06,
P = 0.53; combination versus ramipril, OR 0.95, 0.88–1.04,
P = 0.28). In TRANSCEND, cognitive impairment occurred
in 239 (9%) of the 2694 participants allocated telmisartan
comparedwith245(9%)ofthe2689allocatedaplacebo(OR
0.97, 0.81–1.17, P = 0.76). The corresponding ﬁgures for
cognitive decline were 454 (17%) and 412 (16%; OR 1.10,
0.95–1.27, P = 0.22), respectively.
Recently, the prevention regimen for eﬀectively avoiding
second strokes (PRoFESS) trial [31] investigated the impact
of ARBs on cognitive function in a randomized controlled
design. There were no signiﬁcant diﬀerences in the rate
of cognitive decline or dementia between the treatment
and control groups. These results were very similar to
those in SCOPE. However, PRoFESS several limitations that
obfuscate its conclusions. For example, the duration of
the follow-up period was short, and there was a frequent
discontinuation of the study drug among subjects, and many
patients experienced recurrent stoke requiring termination
of the antihypertensive treatments.
Figaro et al. [32] reported that antihypertensive therapy
with an ARB and diuretic (telmisartan and hydrochloroth-
iazide) caused signiﬁcant improvement in cognitive function
compared to therapy using an ACEI and diuretic (lisinopril
and hydrochlorothiazide). In addition, the observational
study on cognitive function and systolic blood pressure
reduction (OSCAR), an open label trial in 28 countries
designed to evaluate the impact of the ARB eprosartan
on cognitive function, found that a reduction in systolic
blood pressure had an independent negative association with
cognitive decline (odds ratio 0.77; 95% CI: 0.73–0.82).
More recently, prospective cohort study of old (over 65)
subjects demonstrated signiﬁcantly lower hazard rates for
incident dementia with ARBs than with an ACEI (hazard
rate 0.81, 95% CI 0.73–0.90) and other cardiovascular
drugs (0.76, 0.69–0.84). However, the results may not be
generalisable to women because women comprised only 2%
of this cohort [33].
Although it is still not exactly clear how the ARBs confer
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of telmisartan had a preventive eﬀect on cognitive decline in
an AD mouse model (Aβ-injection mouse model). This was
inpartduetotheclearanceofAβ inresponsetoaninhibition
of inﬂammation because of PPAR-gamma activation. Thus,
ARBs that can act as a partial agonist for PPAR-gamma may
provide a beneﬁt for the treatment of dementia, along with
their already blood pressure-lowering eﬀects.
5. Conclusion
It is thought that there is a dependent relationship between
the occurrence of HT and the risk of developing dementia in
old age. This oﬀers promise in the prevention of dementia
because HT is a potentially reversible risk factor.
Recent epidemiological evidence suggests that some
antihypertensive medications may reduce the risk for AD. In
particular, given that Syst-Eur found treating HT with the
dihydropyridine CCB nitrendipine reduced the incidence of
AD by 55%, nitrendipine could prove to be a potentially
reliable option for protection against dementia. Despite
this encouraging evidence, several randomized trials have
failed to support the eﬃcacy of antihypertensive agents in
AD dementia [7, 8]. Thus, at present there is inconsistent
evidence regarding the inﬂuence of antihypertensive drugs
on dementia incidence and/or pathogenesis.
Because current theories assume AD is triggered by the
accumulation of soluble and insoluble forms of β-amyloid,
if high BP can increase the risk of AD, they should then also
lead to an accumulation of β-amyloid. In vitro study, using
primary cortico-hippocampal neuron cultures generated
from AD mouse model, at least 7 candidate antihypertensive
agents including a calcium blocker, a β-adrenergic blocker,
anα-β adrenergicblocker,adiuretic,avasodilatorandARBs,
that signiﬁcantly reduced AD-type β-amyloid protein (Aβ)
accumulation [35]. It is thought that some of these drugs
may have clinical beneﬁts in protecting against progressive
Aβ-related memory disturbance in AD.
Therefore, further prospective randomized studies com-
paring diﬀerent antihypertensive classes are needed to pro-
vide more evidence regarding the eﬀects of antihypertensive
drugs on dementia risk and to determine whether certain
antihypertensive classes provide greater beneﬁts than others.
Inparticular,whethertheseagentspossessspeciﬁcneuropro-
tective properties or increase cerebral perfusion remains to
be clariﬁed.
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